Arvinas, Inc. $ARVN Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB lessened its position in shares of Arvinas, Inc. (NASDAQ:ARVN) by 11.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 495,477 shares of the company’s stock after selling 62,265 shares during the quarter. Nordea Investment Management AB owned about 0.77% of Arvinas worth $5,891,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after acquiring an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in shares of Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after purchasing an additional 3,500 shares during the last quarter. State of Wyoming purchased a new position in shares of Arvinas during the 3rd quarter worth $68,000. Virtus Investment Advisers LLC grew its holdings in shares of Arvinas by 49.3% during the 2nd quarter. Virtus Investment Advisers LLC now owns 12,422 shares of the company’s stock worth $91,000 after purchasing an additional 4,104 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Arvinas during the 3rd quarter worth about $92,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARVN has been the topic of several research analyst reports. Wedbush boosted their price objective on shares of Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Citigroup increased their target price on shares of Arvinas from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Wall Street Zen downgraded shares of Arvinas from a “hold” rating to a “sell” rating in a research note on Monday, March 2nd. Truist Financial set a $10.00 price objective on shares of Arvinas in a report on Wednesday, March 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research report on Monday, December 22nd. Ten analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.88.

Insider Transactions at Arvinas

In other Arvinas news, CFO Andrew Saik sold 5,134 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $61,043.26. Following the completion of the transaction, the chief financial officer owned 159,267 shares of the company’s stock, valued at $1,893,684.63. This trade represents a 3.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Briggs Morrison purchased 20,000 shares of the company’s stock in a transaction on Friday, March 6th. The stock was acquired at an average price of $13.40 per share, with a total value of $268,000.00. Following the purchase, the director owned 96,021 shares of the company’s stock, valued at approximately $1,286,681.40. This represents a 26.31% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have sold 63,864 shares of company stock valued at $802,443. 4.73% of the stock is owned by corporate insiders.

Arvinas Trading Down 0.5%

ARVN opened at $10.87 on Friday. The stock’s 50-day moving average price is $12.57 and its 200 day moving average price is $11.23. Arvinas, Inc. has a 12-month low of $5.90 and a 12-month high of $14.51. The firm has a market cap of $695.26 million, a price-to-earnings ratio of -8.49 and a beta of 1.87.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.55). The firm had revenue of $9.50 million during the quarter, compared to analyst estimates of $37.26 million. Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The business’s revenue was down 84.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.63) earnings per share. On average, research analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Arvinas Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.